Key result
ECG markers (Cornell product and ST depression in V5-V6) predicted clinical heart failure and cardiovascular death in stage B heart failure, but were not incremental to echocardiography.
Why the study?
Do electrocardiographic markers predict the development of clinical heart failure and cardiovascular death in asymptomatic elderly subjects with risk factors for stage B heart failure?
Cohort (n=447)
Do electrocardiographic markers predict the development of clinical heart failure and cardiovascular death in asymptomatic elderly subjects with risk factors for stage B heart failure?
In elderly patients with risk factors for heart failure, ECG markers have low diagnostic sensitivity and do not provide incremental prognostic value over echocardiography for predicting progression to overt heart failure.
ECG markers may aid SBHF detection; hypothesis-generating for ECG-based stratification in non-ischaemic HF.
AIMS: The detection of non-ischaemic (mainly hypertension, diabetes, and obesity) stage B heart failure (SBHF) may facilitate the recognition of those at risk of progression to overt HF and HF prevention. We sought the relationship of specific electrocardiographic (ECG) markers of SBHF to echocardiographic features of SBHF and their prognostic value for development of HF. The ECG markers were Cornell product (Cornell-P), P-wave terminal force in lead V1 (PTFV1), ST depression in lead V5 V6 (minSTmV5V6), and increased heart rate. Echocardiographic assessment of SBHF included left ventricular hypertrophy (LVH), impaired global longitudinal strain (GLS), and diastolic dysfunction (DD). METHOD AND RESULTS: Asymptomatic subjects ≥65 years without prior cardiac history, but with HF risks, were recruited from the local community. At baseline, they underwent clinical assessment, 12-lead ECG, and comprehensive echocardiography. New HF was assessed clinically at mean follow-up of 14 ± 4 months, and echocardiography was repeated in subjects with HF. Of the 447 study subjects (age 71 ± 5, 47% men) with SBHF, 13% had LVH, 32% impaired GLS, and 65% ≥grade I DD (10% ≥grade II DD). Forty were lost to follow-up. Clinical HF developed in 47 of 407, of whom 20% had echocardiographic LVH, 51% abnormal GLS, and 76% DD at baseline. Baseline LVH and abnormal GLS (not grade I DD) were independently associated with outcomes (clinical HF and cardiovascular death). Cornell-P and heart rate (not minSTmV5V6 nor PTFV1) were independently associated with LVH, impaired GLS, and DD. Cornell-P and minSTV5V6 (not heart rate nor PTFV1) were independently associated with outcomes. More ECG abnormalities improved sensitivity, but ECG-markers were not independent of or incremental to echocardiographic markers to predict HF in SBHF. CONCLUSIONS: In this elderly study population, ECG markers showed low diagnostic sensitivity for non-ischaemic SBHF and low prognostic value for outcomes. Cornell-P and minSTmV5V6 had predictive value for outcomes in non-ischaemic SBHF independent of age, gender, and common comorbidities but were not incremental to echocardiography.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2017) conducted a cohort in Stage B heart failure (n=447). Electrocardiographic (ECG) markers was evaluated on Clinical heart failure and cardiovascular death. ECG markers (Cornell product and ST depression in V5-V6) predicted clinical heart failure and cardiovascular death in stage B heart failure, but were not incremental to echocardiography.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: